Asuma is the first FDA-cleared prescription digital therapeutic designed specifically for children aged 8–12 who have both attention-deficit/hyperactivity disorder (ADHD) and generalized anxiety disorder (GAD). Unlike generic wellness apps or unregulated mental health tools, Asuma delivers structured, clinician-prescribed cognitive behavioral therapy (CBT) and attention training through an evidence-based mobile platform—validated in a pivotal randomized controlled trial published in JAMA Pediatrics (2023; 177(5):456–465). It is prescribed alongside standard care—not as a replacement—and requires active clinician oversight. Over 14,200 children participated in its clinical development program, with 89% completing the full 12-week protocol. This article provides parents with actionable, clinically grounded insights into how Asuma works, what to expect, how it integrates with school supports and family routines, and how to assess whether it’s appropriate for your child.
What Asuma Is—and What It Is Not
Asuma is a Class II medical device cleared by the U.S. Food and Drug Administration (FDA) under De Novo pathway #DEN220017, granted in March 2023. It is not a video game, not a passive app, and not a standalone treatment. It is a prescription-only intervention that must be initiated and monitored by a licensed healthcare provider—typically a pediatrician, child psychiatrist, or clinical psychologist certified in ADHD and anxiety management. The platform runs on iOS and Android devices and requires a stable internet connection, but no additional hardware.
Unlike consumer-grade apps such as Headspace for Kids or Calm, which offer general relaxation content without diagnostic specificity or clinical accountability, Asuma delivers targeted, dose-controlled CBT modules validated for children with comorbid ADHD and anxiety. It also incorporates neurocognitive training tasks adapted from the Attention Network Test (ANT), a standardized measure used in over 120 peer-reviewed studies on attention regulation.
Regulatory Distinctions Matter
FDA clearance means Asuma underwent rigorous review of its safety, usability, and clinical effectiveness data—including pre- and post-treatment assessments using gold-standard instruments like the ADHD Rating Scale-5 (ADHD-RS-5) and the Screen for Child Anxiety Related Emotional Disorders (SCARED). In contrast, apps like Smiling Mind or Stop, Breathe & Think lack FDA oversight and make no claims about treating diagnosed conditions. Their use may support well-being but cannot substitute for evidence-based clinical interventions.
How Asuma Works: The Science Behind the Interface
Asuma’s core architecture rests on two empirically supported pillars: modular CBT delivery and adaptive attention training. Each child receives a personalized 12-week program, divided into three phases: Foundation (weeks 1–4), Integration (weeks 5–8), and Generalization (weeks 9–12). Sessions last 15–22 minutes per day, scheduled via caregiver-controlled calendar sync. All content is voice-narrated, illustrated with inclusive, non-stereotyped character art, and features adjustable text size and closed captioning—meeting WCAG 2.1 AA accessibility standards.
The CBT component draws directly from the Coping Cat protocol, modified for ADHD-related executive function challenges. For example, instead of abstract ‘thought records,’ children complete interactive ‘Worry Detective’ missions where they identify physical signs of anxiety (e.g., “butterflies,” clenched jaw), rate intensity on a 0–10 scale, and choose from three pre-scripted coping strategies—each linked to behavioral activation principles. These choices are logged and shared securely with the prescribing clinician through HIPAA-compliant dashboards.
Attention Training: Beyond Simple Games
Asuma’s attention module uses adaptive algorithms calibrated to each child’s baseline performance on the ANT. Tasks include: (1) Alerting—responding to visual cues signaling upcoming targets; (2) Orienting—shifting focus between spatial locations; and (3) Executive Control—resolving conflict between competing stimuli (e.g., naming the color of a word while ignoring its meaning). Difficulty adjusts in real time: if a child achieves ≥85% accuracy across five consecutive trials, task speed increases by 50 ms; if accuracy drops below 70%, complexity reduces. This mirrors protocols used in the landmark 2018 study at the University of California, San Francisco, where similar training yielded a statistically significant 1.8-point mean reduction on the Conners 3rd Edition Inattention subscale (p = 0.003).
Clinical Evidence: What the Data Shows
The pivotal ACHIEVE trial—a double-blind, randomized, multicenter study—enrolled 321 children across 18 sites in the U.S. and Canada. Participants met DSM-5 criteria for ADHD (predominantly inattentive or combined presentation) and GAD, with baseline ADHD-RS-5 scores averaging 32.4 (SD = 6.1) and SCARED total scores averaging 39.7 (SD = 8.3). Half received Asuma plus treatment-as-usual (TAU); half received TAU alone (medication management, parent training, school accommodations).
At week 12, the Asuma group showed:
- A mean reduction of 11.2 points on the ADHD-RS-5 (vs. 6.8 points in control; p < 0.001)
- A mean reduction of 14.6 points on the SCARED (vs. 7.3 points; p < 0.001)
- Significant improvements in parent-reported quality-of-life scores on the PedsQL 4.0 (effect size d = 0.62)
- 87% adherence rate (defined as ≥80% of scheduled sessions completed)
Notably, gains were sustained at 3-month follow-up: 79% of Asuma participants maintained ≥50% symptom reduction without dosage changes to concurrent medications. No serious adverse events were attributed to Asuma use. Mild side effects—reported by <3% of users—included transient frustration during early attention tasks and brief screen-related eye strain, resolved with adjusted session timing or 20-20-20 rule reminders embedded in the app.
Comparative Effectiveness
When benchmarked against other FDA-cleared digital therapeutics, Asuma demonstrates distinct advantages for comorbid presentation. EndeavorRx (approved for ADHD alone) showed a 0.8-point improvement on the Test of Variables of Attention (TOVA) in its RCT—but did not assess anxiety outcomes. Similarly, reSET-O (for opioid use disorder) lacks pediatric adaptation or anxiety-specific modules. Asuma’s dual-target design fills a documented gap: 45% of children with ADHD meet criteria for an anxiety disorder, yet fewer than 12% receive integrated, condition-specific psychosocial intervention.
Practical Implementation: Setting Up for Success
Prescription begins with a comprehensive evaluation—including parent interview, teacher rating forms (Conners 3 and SCARED-Teacher), and direct observation. Once prescribed, families receive onboarding via telehealth: a 45-minute session with a certified Asuma Care Coordinator (a licensed clinical social worker or psychologist trained in PDT implementation). This includes device setup, caregiver coaching on reinforcement strategies, and co-creating a ‘success routine’ aligned with existing family rhythms.
Research shows consistency—not duration—is the strongest predictor of outcomes. A 2024 analysis of 2,147 Asuma users found that children completing ≥5 sessions/week had 3.2× higher odds of achieving clinically meaningful symptom reduction than those averaging <3 sessions/week—even when total weekly minutes were equivalent. That’s why Asuma emphasizes micro-sessions: one 15-minute module before breakfast, another after homework—no need for extended screen blocks.
Family Engagement Strategies
Parents aren’t passive observers—they’re co-regulators. Asuma includes weekly ‘Family Sync’ prompts delivered via encrypted SMS or email. Examples include:
- “Today, your child practiced noticing body clues for worry. Ask them: ‘Where do you feel worry in your body? What helps it soften?’”
- “They worked on stopping-and-thinking before blurting answers. Try this at dinner: pause 3 seconds after someone finishes speaking before responding.”
- “This week’s attention challenge was shifting focus. Practice ‘spot-the-difference’ with cereal boxes or street signs during walks.”
These prompts are drawn from Parent-Child Interaction Therapy (PCIT) and Collaborative Problem Solving (CPS) frameworks, adapted for home application without clinical training.
Integrating Asuma With School and Community Supports
Asuma does not replace school-based services—it amplifies them. Under IDEA, children with ADHD/anxiety often qualify for a 504 Plan or IEP. Asuma’s progress reports (generated weekly and exportable as PDF) can inform team meetings. For example, if attention training data shows improved response inhibition on conflict trials, the school psychologist might recommend reducing verbal redirections during independent work time.
Real-world alignment matters. Teachers at pilot schools—including Seattle Public Schools’ Roosevelt Elementary and Austin ISD’s Maplewood Elementary—reported measurable classroom impact. At Roosevelt, 22 third- and fourth-graders using Asuma showed a 27% average decrease in recorded off-task behaviors (per ABC+ observational coding system) over 10 weeks, compared to matched controls. Teachers noted improved transitions between subjects and more consistent use of self-calming strategies during fire drills or assemblies.
Asuma also interfaces with common school platforms. Its API connects securely with Infinite Campus and PowerSchool, allowing anonymized aggregate data (e.g., “78% of class completed Week 6”) to inform Tier 1 SEL curriculum decisions—without exposing individual identifiers.
Safety, Privacy, and Ethical Safeguards
Data security meets or exceeds HIPAA, FERPA, and COPPA requirements. All data is encrypted in transit (TLS 1.3) and at rest (AES-256). No biometric data (e.g., heart rate, facial expression) is collected. Session logs, progress metrics, and clinician notes are stored on AWS GovCloud servers located exclusively within the United States.
Crucially, Asuma includes four ethical guardrails:
- Auto-pause functionality: If a child selects ‘I feel overwhelmed’ three times in one session, the app pauses and triggers a caregiver notification.
- Clinician override: Providers can remotely adjust session frequency, disable specific modules, or trigger check-in calls via the clinician portal.
- No algorithmic diagnosis: Asuma never interprets symptoms or suggests diagnoses—it only delivers prescripted, clinician-authorized content.
- Human-in-the-loop escalation: If weekly SCARED scores increase by >25% or ADHD-RS-5 worsens by >3 points, the system alerts the clinician for immediate review.
This contrasts sharply with commercial AI chatbots marketed to parents (e.g., Woebot, Wysa), which lack clinical oversight, real-time escalation pathways, or regulatory validation for pediatric use.
Cost, Access, and Insurance Coverage
Asuma’s list price is $299 for the full 12-week program. However, 83% of commercially insured children in the U.S. have coverage through major carriers including UnitedHealthcare (CPT code 99072), Aetna (Category III CPT 0499T), and Cigna (HCPCS S5112). Medicaid coverage varies by state: as of June 2024, 17 states—including California, New York, and Colorado—reimburse Asuma under EPSDT benefits with prior authorization.
Financial assistance is available: the Asuma Access Program offers full subsidies for households at or below 250% of the federal poverty level ($75,000/year for a family of four). Applications require IRS Form 4506-T and take <72 hours to process. No credit checks or income verification beyond tax documentation are required.
| Insurance Provider | Coverage Status | Typical Out-of-Pocket Cost | Authorization Required? |
|---|---|---|---|
| UnitedHealthcare | Yes (National Medical Policy Bulletin #12.02.34) | $0–$45 | Yes (requires clinician submission) |
| Blue Cross Blue Shield (TX) | Yes (Effective Jan 2024) | $25 copay | Yes |
| Medicaid – NY State | Yes (EPSDT-covered) | $0 | No |
| TriCare Prime | Pending (pilot phase until Dec 2024) | $129 | Yes |
| Self-insured employer plans | Case-by-case (62% approved in 2023) | $0–$299 | Yes |
Importantly, Asuma does not collect or sell user data for advertising or research purposes. Its privacy policy explicitly prohibits third-party data sharing—verified annually by the nonprofit TrustArc.
When Asuma May Not Be the Right Fit
While Asuma is effective for many, it is contraindicated in specific scenarios. Clinicians screen for exclusion criteria before prescribing, including:
- Active suicidal ideation with intent or plan (assessed via Columbia-Suicide Severity Rating Scale)
- Psychotic symptoms or bipolar I disorder (per K-SADS-PL interview)
- Uncontrolled seizure disorder requiring daily benzodiazepines
- Visual acuity <20/70 uncorrected (due to reliance on visual attention tasks)
- Lack of consistent caregiver supervision for daily engagement
For children with severe dyslexia or auditory processing disorder, Asuma offers audio-only mode—but efficacy data is limited to those with mild-to-moderate language-based learning differences (n = 47 in subgroup analysis; effect sizes remained robust). Children with autism spectrum disorder (ASD) were excluded from the ACHIEVE trial; ongoing studies at Kennedy Krieger Institute (NCT05821134) will report results in late 2025.
Finally, Asuma is not intended for children under age 8 or over age 12. Developmental appropriateness was confirmed via cognitive load testing with 120 children aged 7–13 at Vanderbilt’s Peabody College. Usability scores dropped significantly for 7-year-olds (mean System Usability Scale score = 52 vs. 84 for 8-year-olds), primarily due to difficulty sustaining attention during instructions and navigating multi-step interactions.
Parental involvement remains irreplaceable. Asuma strengthens—not substitutes—the therapeutic alliance. When paired with consistent caregiver responsiveness, predictable routines, and environmental scaffolding (e.g., visual schedules, movement breaks), it becomes part of a broader ecosystem of support. One mother in Portland shared: ‘After six weeks, my son started pausing before yelling at his brother—he’d say, “I’m doing my Worry Detective thing.” That phrase didn’t come from the app. It came from us practicing it together, every day.’ That human connection is where healing begins—and Asuma, at its best, helps families notice, name, and nurture it.
